Attributes | Values |
---|
rdf:type
| |
Description
| - The median age was 68 years, and the glomerular filtration rate (GFR) was 18 ml per minute per 1.73 m(2) of body-surface area. A total of 25 patients in the rituximab group (76%) and 9 patients in the control group (82%) had a sustained remission (P=0.68). Severe adverse events occurred in 14 patients in the rituximab group (42%) and 4 patients in the control group (36%) (P=0.77). Six of the 33 patients in the rituximab group (18%) and 2 of the 11 patients in the control group (18%) died (P=1.00). The median increase in the GFR between 0 and 12 months was 19 ml per minute in the rituximab group and 15 ml per minute in the control group (P=0.14).
- The median age was 68 years, and the glomerular filtration rate (GFR) was 18 ml per minute per 1.73 m(2) of body-surface area. A total of 25 patients in the rituximab group (76%) and 9 patients in the control group (82%) had a sustained remission (P=0.68). Severe adverse events occurred in 14 patients in the rituximab group (42%) and 4 patients in the control group (36%) (P=0.77). Six of the 33 patients in the rituximab group (18%) and 2 of the 11 patients in the control group (18%) died (P=1.00). The median increase in the GFR between 0 and 12 months was 19 ml per minute in the rituximab group and 15 ml per minute in the control group (P=0.14). (en)
|
Title
| - Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
- Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis (en)
|
skos:prefLabel
| - Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
- Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis (en)
|
skos:notation
| - RIV/00064165:_____/10:6831!RIV11-MZ0-00064165
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00064165:_____/10:6831
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Treatment with rituximab; cyclophosphamide; ANCA - associated renal vasculitis; remissin; reates of death (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - New England Journal of Medicine
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Jayne, David
- Tesař, Vladimír
- Segelmark, Marten
- Luqmani, Raashid
- Walsh, Michael
- Westman, Kerstin
- Tervaert, Jan Williem
- Hauser, Thomas
- Jones, Rachel
- Morgan, Matew
- Paassen, Pieter
- Peh, Chem Au
- Savage, Carolina
- Walsh, Dorothy
|
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |